European Journal of Cancer最新文献

{"title":"Clinical and imaging strategies for the assessment of the ocular side effects of systemic targeted anti-cancer therapies","authors":"Luke Michaels ,&nbsp;Maha Noor ,&nbsp;Tariq Aslam","doi":"10.1016/j.ejca.2025.115452","DOIUrl":"10.1016/j.ejca.2025.115452","url":null,"abstract":"<div><div>Systemic targeted anti-cancer therapies selectively target cancerous cells whilst limiting systemic side effects. The eye however, is a particularly sensitive organ and the expanding use of the newer targeted chemotherapy agents has been associated with multiple ocular side effects. In this review we provide an update of the ocular side effects of the newer targeted chemotherapy agents along with suggested minimum, pragmatic, evidence-based strategies for effective screening or monitoring for potential ocular side effects. This framework is designed to guide oncologists, trial managers, protocol developers and regulatory authorities so that appropriate ophthalmic clinical examinations and non-invasive modern imaging can be requested and commissioned according to a patient’s specific treatment.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115452"},"PeriodicalIF":7.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nordic colorectal cancer screening programmes: A comparison of organization, operation, and quality indicators","authors":"Susanne Fogh Jørgensen ,&nbsp;Sisse Helle Njor ,&nbsp;Aapeli Nevala ,&nbsp;Birger Pålsson ,&nbsp;Kristin Ranheim Randel ,&nbsp;Ágúst Ingi Ágústsson ,&nbsp;Tytti Sarkeala ,&nbsp;Anna Lisa Schult ,&nbsp;Rikard Svernlöv ,&nbsp;Helgi Birgisson ,&nbsp;The Nordic Colorectal cancer Screening Network","doi":"10.1016/j.ejca.2025.115444","DOIUrl":"10.1016/j.ejca.2025.115444","url":null,"abstract":"<div><h3>Introduction</h3><div>While comparison studies are common in the Nordic countries, important differences need to be illuminated to understand the comparability of future studies within colorectal cancer (CRC) screening research.</div><div>Therefore, a systematic overview of similarities and differences in the CRC screening programmes in Denmark, Finland, Iceland, Norway, and Sweden was conducted</div></div><div><h3>Methods</h3><div>Information from each country was gathered through the Nordic CRC screening network, which includes experts in CRC screening from the participating countries.</div><div>A timeline describing preceding pilot studies and national roll-outs in all countries was established. Furthermore, the screening flow in each country and the quality indicator monitoring including performance standards were presented.</div></div><div><h3>Results</h3><div>During 2014–2024, all five Nordic countries implemented CRC screening using faecal immunochemical testing (FIT) but with different implementation strategies and cut-off values. Taking colonoscopy resources into account, gradual implementation strategies were used in all countries, but with different paces. Quality monitoring follows the European recommendations with some variation; however key performance indicators such as adenoma detection rates (ADR), colonoscopy complication rates, serrated polyp detection, post-colonoscopy CRC (PCCRC) rates, and interval cancer rates, are monitored by all countries.</div></div><div><h3>Conclusion</h3><div>This paper may serve as a key reference for future research and comparison studies across the Nordic countries. The variation found in countries with similar health care systems might serve as natural experiments in future studies. Furthermore, this overview shows that there might be room for improvements in the monitoring of certain quality indicators to facilitate quality improvement efforts in all Nordic countries.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115444"},"PeriodicalIF":7.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143876621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study","authors":"Ali Shamseddine ,&nbsp;Rim Turfa ,&nbsp;Laudy Chehade ,&nbsp;Youssef H. Zeidan ,&nbsp;Ziad El Husseini ,&nbsp;Malek Kreidieh ,&nbsp;Youssef Bouferraa ,&nbsp;Charbel Elias ,&nbsp;Joseph Kattan ,&nbsp;Ibrahim Khalifeh ,&nbsp;Deborah Mukherji ,&nbsp;Sally Temraz ,&nbsp;Yasser Shaib ,&nbsp;Assaad Soweid ,&nbsp;Kholoud Alqasem ,&nbsp;Rula Amarin ,&nbsp;Tala Al Awabdeh ,&nbsp;Samer Deeba ,&nbsp;Samer Doughan ,&nbsp;Issa Mohamad ,&nbsp;Fady Geara","doi":"10.1016/j.ejca.2025.115428","DOIUrl":"10.1016/j.ejca.2025.115428","url":null,"abstract":"<div><h3>Background</h3><div>Total neoadjuvant therapy(TNT) has improved complete pathologic response (pCR) rate and disease-free survival (DFS) in locally advanced rectal cancer (LARC), though an increased local recurrence rate (LRR) with short-course radiotherapy (SCRT) is concerning. Synergism between immunotherapy and radiotherapy may improve outcomes in LARC, even where microsatellite stable (MSS) tumours exist. The Averectal trial evaluated SCRT, followed by chemotherapy and immunotherapy with avelumab and total mesorectal excision (TME) in these patients.</div></div><div><h3>Methods</h3><div>Patients with LARC received SCRT (5 Gy x5 fractions), 6 cycles of mFOLFOX-6 plus avelumab every 2 weeks, followed by TME in an investigator-initiated, open-label, single-arm, multicentre, phase II study. The primary outcome was pCR vs. historical control. Secondary outcomes were 3-year DFS, local recurrence rate (LR) and the association of the ImmunoScore (IS) with outcomes including pCR, safety, and quality of life (QoL).</div></div><div><h3>Results</h3><div>Out Of 44 MSS patients enrolled from 3 centres (July 2018 −October 2020), 40 completed treatment and analysed (65 % male, median age 58.5 [31.0, 74.0] years). Median follow-up was 44 months (11.4, 51.4). Fifteen patients (37.5 %) achieved pCR; and 67.5 % had a major pathologic response. Mean DFS was 42 months (37.9, 46.1). Mean OS was 46.3 months (44.4, 48.2). Median DFS and OS were not reached. Three-year DFS was 85 %. LRR was 2.5 %. Patients with vs. without pCR had higher mean IS (68 vs. 52, p = 0.036). Serious adverse events occurred in 23.5 % (one was related to avelumab). Three patients died (7.5 %), due to disease progression. QOL was similar between baseline and last follow-up.</div></div><div><h3>Conclusion</h3><div>Adding avelumab to neoadjuvant chemotherapy mFOLFOX6 after SCRT, followed by TME, improved pCR without increasing LRR, with acceptable toxicity and QOL.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115428"},"PeriodicalIF":7.6,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence to predict cancer risk, are we there yet? A comprehensive review across cancer types","authors":"Alessio Felici ,&nbsp;Giulia Peduzzi ,&nbsp;Roberto Pellungrini ,&nbsp;Daniele Campa","doi":"10.1016/j.ejca.2025.115440","DOIUrl":"10.1016/j.ejca.2025.115440","url":null,"abstract":"<div><div>Cancer remains the second leading cause of death worldwide, representing a substantial challenge to global health. Although traditional risk prediction models have played a crucial role in epidemiology of several cancer types, they have limitations especially in the ability to process complex and multidimensional data. In contrast, artificial intelligence (AI) approaches represent a promising solution to overcome this limitation. AI techniques have the potential to identify complex patterns and relationships in data that traditional methods might overlook, making them especially useful for handling large and heterogeneous datasets analysed in cancer research. This review first examines the current state of the art of AI techniques, highlighting their differences and suitability for various data types. Then, offers a comprehensive analysis of the literature, focusing on the application of AI approaches in nineteen cancer types (bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, gynaecological cancers, head and neck cancer, haematological cancers, kidney cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer and overall cancer), evaluating the models, metrics, and exposure variables used. Finally, the review discusses the application of AI in the clinical practice, along with an assessment of its potential limitations and future directions.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115440"},"PeriodicalIF":7.6,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","authors":"Karin Jordan ,&nbsp;Evandro de Azambuja ,&nbsp;María Ángeles García del Barrio ,&nbsp;Franziska Jahn ,&nbsp;Mario Di Palma ,&nbsp;Florian Scotté ,&nbsp;Alex Molassiotis ,&nbsp;Matti Aapro","doi":"10.1016/j.ejca.2025.115451","DOIUrl":"10.1016/j.ejca.2025.115451","url":null,"abstract":"<div><div>The MASCC/ESMO guidelines for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting were updated in 2023 by a Consensus Committee of 34 multidisciplinary international healthcare professionals and three patient advocates. Guideline-recommended prophylactic anti-emetic strategies can control chemotherapy-induced nausea and vomiting (CINV) in many patients, but unaddressed issues remain. Across a series of meetings, we evaluated these guidelines to identify possible evidence gaps which warrant further exploration. Key topics identified and discussed included the use of dexamethasone-sparing regimens with cisplatin (and other non-anthracycline and cyclophosphamide)-based highly emetogenic chemotherapy regimens, the importance of individual patient risk factors for CINV, the use of a second agent in patients receiving low emetogenic chemotherapy, how to manage CINV with certain new antibody-drug conjugates, the most appropriate approach for managing breakthrough CINV, the options for patients with CINV even after following best guidance, the use of lower than standard doses of olanzapine (&lt;10 mg/day), and the management of long-delayed CINV and CINV in patients receiving oral therapies. Through identifying the current gaps in the updated MASCC/ESMO guidelines and discussing the available evidence, we aim to address these issues and support oncologists who may encounter them in clinical practice. These and other questions need to be considered to help ensure choice of anti-emetic treatments provide optimal effectiveness in clinical practice.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115451"},"PeriodicalIF":7.6,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143876620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial","authors":"L.L. Hoeijmakers ,&nbsp;E.A. Rozeman ,&nbsp;M. Lopez-Yurda ,&nbsp;L.G. Grijpink-Ongering ,&nbsp;B.C. Heeres ,&nbsp;B.A. van de Wiel ,&nbsp;C. Flohil ,&nbsp;A. Sari ,&nbsp;S.W.T.P.J. Heijmink ,&nbsp;D. van den Broek ,&nbsp;A. Broeks ,&nbsp;J.W.B. de Groot ,&nbsp;M.A. Vollebergh ,&nbsp;S. Wilgenhof ,&nbsp;J.V. van Thienen ,&nbsp;J.B.A.G. Haanen ,&nbsp;C.U. Blank","doi":"10.1016/j.ejca.2025.115431","DOIUrl":"10.1016/j.ejca.2025.115431","url":null,"abstract":"<div><h3>Background</h3><div>The addition of targeted therapy (TT) to immune checkpoint inhibitors has been shown to transiently increase immune infiltration in melanoma. This formed the rationale for the IMPemBra trial, which showed a numerical increase in progression-free survival (PFS) in patients treated with short-term/intermittent TT and anti-PD1 compared to anti-PD1 alone. In this report, the final toxicity-analysis, 5-year PFS and exploratory analysis of overall survival (OS) will be reported, together with an analysis of subsequent therapies.</div></div><div><h3>Patients and methods</h3><div>32 treatment-naïve patients with a <em>BRAFV600E/K</em>-mutated advanced melanoma were treated with 2 cycles of pembrolizumab 200 mg every 3 weeks, followed by randomization to continue pembrolizumab monotherapy for six weeks in cohort-1 versus pembrolizumab plus intermittent dabrafenib 150 mg BID + trametinib 2 mg QD 2×1-week (cohort 2), 2×2-weeks (cohort 3), or 1×6-weeks (cohort 4). After week 12, all patients continued pembrolizumab monotherapy for a maximum of 2 years.</div></div><div><h3>Results</h3><div>With a median follow-up of 73 months, final grade 3–4 immune-related adverse events are 12 % (cohort 1), 12 % (cohort 2), 38 % (cohort 3) and 63 % (cohort 4). Estimated 5-year PFS and OS rates were 25 % and 50 % for pembrolizumab monotherapy (cohort-1) and 46 % and 71 % for pembrolizumab + intermittent TT (cohorts 2–4). Estimated 5-year PFS and OS were 63 % and 63 % (cohort 2), 38 % and 75 % (cohort 3), and 38 % and 75 % (cohort 4), respectively. The subsequent therapies were balanced between cohorts. Patients treated with short-term/intermittent schemes achieved durable responses upon subsequent TT again.</div></div><div><h3>Conclusion</h3><div>This survival update from the IMPemBra trial demonstrates that combination of short-term TT and checkpoint inhibition can induce long-lasting responses, warranting further analyses in larger cohorts, and in a randomized design.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115431"},"PeriodicalIF":7.6,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Association between local treatment modalities and event-free survival, overall survival, and local recurrence in patients with localised Ewing Sarcoma. Report from the Ewing 2008 trial” [Eur J Cancer 192 (2023) 113260]","authors":"Philip Heesen ,&nbsp;Andreas Ranft ,&nbsp;Vivek Bhadri ,&nbsp;Benedicte Brichard ,&nbsp;Stephane Collaud ,&nbsp;Sona Cyprova ,&nbsp;Hans Eich ,&nbsp;Torben Ek ,&nbsp;Hans Gelderblom ,&nbsp;Jendrik Hardes ,&nbsp;Lianne Haveman ,&nbsp;Susanne Jabar ,&nbsp;Wolfgang Hartmann ,&nbsp;Dimosthenis Andreou ,&nbsp;Peter Hauser ,&nbsp;Josephine Kersting ,&nbsp;Heribert Juergens ,&nbsp;Jukka Kanerva ,&nbsp;Thomas Kühne ,&nbsp;Anna Raciborska ,&nbsp;Uta Dirksen","doi":"10.1016/j.ejca.2025.115441","DOIUrl":"10.1016/j.ejca.2025.115441","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115441"},"PeriodicalIF":7.6,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"German S2k-guideline on diagnostics, treatment and surveillance of low-grade appendiceal mucinous neoplasms (LAMN)","authors":"Franziska Köhler ,&nbsp;Dirk Arnold ,&nbsp;Daniela Aust ,&nbsp;Johannes Betge ,&nbsp;Ines B. Brecht ,&nbsp;Christoph-Thomas Germer ,&nbsp;Bernd Grouven ,&nbsp;Philipp Harter ,&nbsp;Stefan Kasper-Virchow ,&nbsp;Kai Koslowski ,&nbsp;Hannes Philipp Neeff ,&nbsp;Jens Neumann ,&nbsp;Pompiliu Piso ,&nbsp;Beate Rau ,&nbsp;Dominik T. Schneider ,&nbsp;Andreas G. Schreyer ,&nbsp;Maria A. Kröplin ,&nbsp;Armin Wiegering","doi":"10.1016/j.ejca.2025.115430","DOIUrl":"10.1016/j.ejca.2025.115430","url":null,"abstract":"<div><div>The German guideline for low-grade appendiceal mucinous neoplasms (LAMN) and pseudomyxoma peritonei (PMP) offers comprehensive recommendations for diagnosis, treatment, and surveillance of these rare tumours. Developed by the German Society of General and Visceral Surgery (DGAV) alongside 14 other medical societies or task groups, this S2k-guideline addresses the need for standardised care in the absence of high-quality randomized controlled trials due to the rarity of LAMN and PMP. The guideline covers classification and staging of LAMN according to WHO and TNM systems, emphasising histological analysis and surgical protocols aimed at preventing intra-abdominal perforation. Diagnostic recommendations include imaging (MRI or CT) and preoperative tumour marker assessment, along with screening colonoscopies to rule out synchronous colorectal malignancies in specific age groups. Therapeutic guidelines focus on the importance of treatment in specialised centres with expertise in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). CRS combined with HIPEC is recommended for patients with PMP, with an emphasis on multidisciplinary team involvement and psycho-oncological support. The guideline outlines post-treatment surveillance, recommending six-monthly imaging and tumour marker evaluations for five years. It highlights the importance of considering fertility preservation in patients undergoing cytoreductive surgery and HIPEC. This consensus-based guideline aims to enhance the quality and consistency of care for patients with LAMN and PMP, offering a structured approach despite limited clinical trial data.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115430"},"PeriodicalIF":7.6,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial","authors":"Giacomo Biganzoli ,&nbsp;Edoardo Isnaldi ,&nbsp;François Richard ,&nbsp;Giuseppe Marano ,&nbsp;Patrizia Boracchi ,&nbsp;Marion Maetens ,&nbsp;Giuseppe Floris ,&nbsp;Patrick Neven ,&nbsp;Guy Jerusalem ,&nbsp;Elisabetta Munzone ,&nbsp;Erika Hitre ,&nbsp;Andrea Gombos ,&nbsp;Alastair Thompson ,&nbsp;Stefan Aebi ,&nbsp;Roswitha Kammler ,&nbsp;Patrizia Dell’Orto ,&nbsp;Giuseppe Viale ,&nbsp;Meredith M. Regan ,&nbsp;Marco Colleoni ,&nbsp;Elia Biganzoli ,&nbsp;Christine Desmedt","doi":"10.1016/j.ejca.2025.115438","DOIUrl":"10.1016/j.ejca.2025.115438","url":null,"abstract":"<div><h3>Background</h3><div>Obesity is associated with a greater risk of developing distant recurrences in patients with estrogen receptor-positive (ER+) breast cancer. This association is however poorly investigated in patients treated with extended endocrine treatment (ET). We therefore evaluated the prognostic role of BMI in the SOLE trial, where postmenopausal patients, after having completed 4–6 years of adjuvant ET, were treated with 5 additional years of continuous or intermittent letrozole.</div></div><div><h3>Patients &amp; methods</h3><div>We considered the 3606 patients with ER+ /HER2- lymph node-positive BC with available BMI from the SOLE trial (NCT00553410). Distant-recurrence free interval (DRFI) was the main endpoint, and breast cancer-free interval (BCFI), disease-free survival (DFS) and overall survival (OS) secondary endpoints. Adjusted risk ratios (RR) for distant metastases were estimated with crude cumulative incidence models.</div></div><div><h3>Results</h3><div>38.6 % of the patients were underweight or normal weight, 36.5 % overweight and 24.9 % obese. BMI was associated with age, tumor size, number of positive lymph nodes, menopausal status and type of prior ET. In the adjusted analyses, the prognostic value of BMI was dependent on prior ET and extended ET arm (second-order interaction p-value&lt;0.001 for DRFI, BCFI and DFS, but not for OS). For instance, in patients treated with both a selective estrogen receptor modulator and an aromatase inhibitor in the first five years, obesity, as compared to normal-weight, was associated with better (RR_DRFI=0.61, 95 %CI: 0.42–0.90) and worse (RR_DRFI=2.31, 95 %CI: 1.41–3.78) outcomes in the adjusted models, in patients treated with continuous and intermittent letrozole in the extended ET, respectively.</div></div><div><h3>Conclusion</h3><div>We observed that the prognostic relation of BMI changes according to the type of adjuvant ET and mode of administration of extended AI. This warrants further investigation.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115438"},"PeriodicalIF":7.6,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment","authors":"Hiroshi Imaoka ,&nbsp;Masafumi Ikeda ,&nbsp;Masato Ozaka ,&nbsp;Kotoe Oshima ,&nbsp;Naohiro Okano ,&nbsp;Satoshi Shimizu ,&nbsp;Hidetaka Tsumura ,&nbsp;Yoshito Komatsu ,&nbsp;Taro Yamashita ,&nbsp;Shigeki Kataoka ,&nbsp;Hiroaki Nagano ,&nbsp;Terumasa Hisano ,&nbsp;Mitsuhito Sasaki ,&nbsp;Satoshi Kobayashi ,&nbsp;Taito Fukushima ,&nbsp;Shuichi Mitsunaga ,&nbsp;Takaaki Furukawa ,&nbsp;Satoshi Hamauchi ,&nbsp;Makoto Ueno ,&nbsp;Junji Furuse","doi":"10.1016/j.ejca.2025.115424","DOIUrl":"10.1016/j.ejca.2025.115424","url":null,"abstract":"<div><h3>Background</h3><div>Liposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) improves survival in gemcitabine-refractory metastatic pancreatic cancer (PC) but requires a central venous port. S-1, an oral fluoropyrimidine with proven efficacy in PC, may replace 5-FU/LV in nal-IRI plus 5-FU/LV, potentially enhancing both convenience and antitumor effect.</div></div><div><h3>Methods</h3><div>This single-arm, open-label, phase 1/2 study included patients with histologically or cytologically confirmed adenocarcinoma, aged 20–80 years, an Eastern Cooperative Oncology Group performance status of 0–1, with metastatic disease, and refractory to gemcitabine-based treatment. The primary endpoint in phase 1 part was the frequency of dose-limiting toxicity (DLT) to nal-IRI plus S-1. The primary endpoint in phase 2 part was overall survival. This trial was registered in the Japan Registry of Clinical Trials database (jRCTs031210040).</div></div><div><h3>Results</h3><div>In phase 1 part, one patient with DLT was observed at nal-IRI 70 mg/m² (day 1) with S-1 80 mg/m²/day (day 1–7) in a 2-week cycle, establishing this as the recommended phase 2 dose (RP2D). Forty-nine patients from phase 1 (n = 6) and phase 2 part (n = 43) were treated with the RP2D, and their results were pooled. Median overall survival was 10.3 months (95 % confidence interval, 8.1–12.0 months). A confirmed partial response was achieved in 10 patients (20.4 %). The most frequent treatment-emergent adverse events were hypoalbuminemia (98.0 %), anemia (98.0 %), and anorexia (81.6 %). There were no treatment-related deaths.</div></div><div><h3>Conclusions</h3><div>This study demonstrated that nal-IRI plus S-1 exhibited promising efficacy and an acceptable safety profile in patients with metastatic PC refractory to gemcitabine-based treatment.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"222 ","pages":"Article 115424"},"PeriodicalIF":7.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}